|
Apr 10
|
Omeros Announces the Omeros Oncology Clinical Steering Committee for AML to Help Guide Omeros’ Proprietary OncotoX-AML Clinical Program
|
|
Apr 8
|
Omeros Corporation To Introduce Its Proprietary T-CAT™ Program for the Treatment of Multidrug-Resistant Pathogens in Plenary Session at Upcoming European Congress on Infectious Diseases
|
|
Mar 13
|
Omeros Corporation Receives Commitment of Over $4 Million from NIDA for Further Development of the Company’s OMS527 Program to Treat Cocaine Use Disorder
|
|
Feb 21
|
Omeros announces results for narsoplimab expanded access program
|
|
Feb 20
|
Omeros Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMA
|
|
Jan 16
|
Omeros Announces Update on Statistical Analysis of Narsoplimab Pivotal Trial Primary Endpoint
|
|
Sep 3
|
Retail investors account for 52% of Omeros Corporation's (NASDAQ:OMER) ownership, while institutions account for 43%
|
|
Aug 7
|
Omeros: Q2 Earnings Snapshot
|
|
Aug 7
|
Omeros Corporation Reports Second Quarter 2024 Financial Results
|
|
Aug 5
|
Omeros Corporation to Announce Second Quarter Financial Results on August 7, 2024
|
|
May 16
|
Q1 2024 Omeros Corp Earnings Call
|
|
May 16
|
Omeros Corp (OMER) Q1 2024 Earnings Call Transcript Highlights: Financial Shifts and Strategic ...
|
|
May 15
|
Omeros Corporation Reports First Quarter 2024 Financial Results
|
|
May 10
|
Omeros Corporation to Announce First Quarter Financial Results on May 15, 2024
|
|
May 9
|
Omeros Corporation Announces Upcoming Presentations at 2024 European Hematology Association (EHA) Hybrid Congress
|
|
Apr 2
|
Q4 2023 Omeros Corp Earnings Call
|
|
Apr 2
|
Omeros Corporation (NASDAQ:OMER) Q4 2023 Earnings Call Transcript
|
|
Apr 1
|
Omeros Corp (OMER) Reports Fourth Quarter and Year-End 2023 Financial Results
|
|
Apr 1
|
Omeros Corporation Reports Fourth Quarter and Year-End 2023 Financial Results
|
|
Mar 27
|
Omeros Corporation to Announce Fourth Quarter and Year-End Financial Results on April 1, 2024
|